ARDELYX, INC.
No SEC Form 4 filings for $ARDX in the last 30 days.
See all $ARDX insider activity →Ardelyx reported real-world data at ASN Kidney Week 2026, showing serum phosphate reductions of 0.80–1.55 mg/dL at six months after XPHOZAH initiation. 16%–41% of patients reached <5.5 mg/dL, and 60%–70% remained on therapy at 180 days.
Ardelyx reported real-world data at ACG 2026 showing a median reduction in GI-related healthcare visits from 4.5 to 3.0 in the year after IBSRELA initiation among 470 adults with IBS-C. The data reinforces IBSRELA's clinical utility and signals pipeline progress into CIC.
Ardelyx Inc. (ARDX) will present research on hyperphosphatemia treatment at the American Society of Nephrology Kidney Week 2026. Presentations include studies on tenapanor's effectiveness, patient perspectives, and long-term impacts. The company will also host an exhibitor session on XPHOZAH (tenapanor). XPHOZAH is FDA-approved for reducing serum phosphorus in dialysis patients, with diarrhea as the most common side effect.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ARDX (ARDELYX, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ARDX coverage spans earnings, financial news and technology.
Positive efficacy and persistence data may boost investor confidence in XPHOZAH.
The data suggests IBSRELA improves patient outcomes, which could boost Ardelyx's commercial outlook and future pipeline value.
The conference abstracts provide modest new data on tenapanor, likely generating limited investor interest.
Guidance reaffirmation supports near‑term upside, but higher operating expenses may temper enthusiasm.
Insider sale by the chief executive may signal reduced confidence or portfolio rebalancing.
AlphAI scores every news story that mentions ARDX with an AI model for sentiment and relevance, and aggregates insider trades from ARDELYX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ardelyx reported real-world data at ASN Kidney Week 2026, showing serum phosphate reductions of 0.80–1.55 mg/dL at six months after XPHOZAH initiation. 16%–41% of patients reached <5.5 mg/dL, and 60%–70% remained on therapy at 180 days.
1 min readArdelyx reported real-world data at ACG 2026 showing a median reduction in GI-related healthcare visits from 4.5 to 3.0 in the year after IBSRELA initiation among 470 adults with IBS-C. The data reinforces IBSRELA's clinical utility and signals pipeline progress into CIC.
1 min readArdelyx Inc. (ARDX) will present research on hyperphosphatemia treatment at the American Society of Nephrology Kidney Week 2026. Presentations include studies on tenapanor's effectiveness, patient perspectives, and long-term impacts. The company will also host an exhibitor session on XPHOZAH (tenapanor). XPHOZAH is FDA-approved for reducing serum phosphorus in dialysis patients, with diarrhea as the most common side effect.
1 min readArdelyx Inc. (ARDX) shares rose 2% after-hours, reaffirming 2026 guidance for IBSRELA and XPHOZAH, targeting $500M+ revenue this year. The company expects $1B IBSRELA sales by 2029 and $750M peak for XPHOZAH. Profitability is anticipated soon, with operating expenses guided at $520M. Analysts rate ARDX 'Buy' with a 12-month average price target of $16.33, implying over 200% upside.
1 min readRAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.
1 min readArdelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.
1 min readArdelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.
6 min readAccording to exchange data compiled by Bloomberg and reported by Investing.com, Ardelyx Inc. options activity rose Friday morning to 11,147 contracts, with puts dominating (10,676). The October 16, 2026 $4 put led with 10,004 contracts. Ardelyx shares fell 18.4% to $3.98, and 3-month volatility rose to 74.93%.
2 min readArdelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
4 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow
5 min read
